Overview

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Status:
NOT_YET_RECRUITING

Trial end date:
2030-01-16

Target enrollment:

Participant gender:

Summary

This study specifically aims to evaluate how well GSK5733584 works in treating ovarian cancer compared to standard treatments. The study also assesses whether GSK5733584 is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.

Phase:

PHASE3

Details

Lead Sponsor:

GlaxoSmithKline

Collaborators:

European Network of Gynaecological Oncological Trial Groups (ENGOT)
GOG Foundation

Treatments:

Gemcitabine
liposomal doxorubicin
Paclitaxel
Topotecan